NFKB1 and type 2 diabetes mellitus: Here we investigate (a) the role of NF-κB activation in the cardiac dysfunction caused by HFD with or without sepsis, (b) the effect of linagliptin treatment on cardiac performance in the model of sepsis and T2DM.